Applied Therapeutics Shares Hit 52-Week High on Govorestat Filings
January 03 2024 - 10:20AM
Dow Jones News
By Colin Kellaher
Applied Therapeutics shares rose sharply and hit a new 52-week
high on Wednesday after the clinical-stage biopharmaceutical
company reported a pair of regulatory advances for its lead product
candidate.
Shares of the New York company were recently changing hands at
$3.98, up 9.2%, after touching a 52-week high of $4.42 earlier in
the session.
Applied said it filed last month for U.S. Food and Drug
Administration approval of govorestat for the treatment of classic
galactosemia, a rare genetic metabolic disease for which there is
currently no available treatment.
The company also said the European Medicines Agency has
validated and accepted for review its application seeking approval
of the drug in the European Union.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 03, 2024 11:05 ET (16:05 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Applied Therapeutics (NASDAQ:APLT)
Historical Stock Chart
From Apr 2024 to May 2024
Applied Therapeutics (NASDAQ:APLT)
Historical Stock Chart
From May 2023 to May 2024